One Year On: WHO Concludes Wuhan Probe; CanSino Vaccine 66% Effective
WHO Answers Some Questions, Raises Others
A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.
You may also be interested in...
China Approves SinoVac's CoronaVac, As 50.6% Efficacy Reported
SinoVac has obtained conditional approval in China for its COVID-19 vaccine CoronaVac, while new clinical data released by the company show a large difference in protection rates in two separate trials, in one case barely above the WHO threshold.
J&J’s One-Shot Vaccine Shows 66% Efficacy, But Company Says There’s More To It
The drug maker played up the 85% prevention of severe disease and 100% prevention of hospitalization and death despite lower overall efficacy relative to mRNA vaccines.
One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.